Congruently, transcriptomic data from human MASLD/MASH patients revealed reduced hepatic MARCHF6 expression alongside an increase in that of the lipogenic genes SREBF1, FASN, and SCD1. The gene discussed is SREBF1; the disease is metabolic dysfunction-associated steatotic liver disease.